The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.80
Bid: 41.05
Ask: 41.65
Change: 0.20 (0.49%)
Spread: 0.60 (1.462%)
Open: 40.40
High: 41.80
Low: 40.00
Prev. Close: 40.60
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Preliminary Results

5 Mar 2019 07:00

RNS Number : 8147R
Futura Medical PLC
05 March 2019
 

 

Notice of Preliminary Results

05 March 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, will announce its preliminary results for the year ended 31 December 2018 on Wednesday 10 April 2019.

James Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at the office of N+1 Singer at 1 Bartholomew Lane, London EC2N 2AX.

A copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site.

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670 

Nominated Adviser and Broker:N+1 SingerAubrey Powell/ Ben Farrow (Corporate Finance)

Mia Gardner/ Tom Salvesen (Corporate Broking)Tel: +44 (0) 20 7496 3000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORKMGGFZDMGLZZ
Date   Source Headline
29th Apr 20247:00 amRNSDirectors’ / PDMR Dealing and Grant of Options
10th Apr 20247:00 amRNSResults for the Year ended 31 December 2023
25th Mar 20247:00 amRNSNotice of Results and Investor Presentation
14th Feb 20247:00 amRNSEroxon to be available on prescription
6th Feb 20247:01 amRNSTrading Update
6th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
17th Jan 20247:00 amRNSDirector/PDMR Dealing
17th Jan 20247:00 amRNSRemuneration of Non-Exec Directors & Voting Rights
15th Jan 20247:00 amRNSFutura Medical extends collaboration with Cooper
9th Jan 20247:00 amRNSAppointment of Roy Davis as Non-Executive Director
30th Nov 20233:10 pmRNSTotal Voting Rights
30th Nov 20233:10 pmRNSBlock Listing Six Monthly Return
7th Nov 20237:00 amRNSFutura expands partnership with M8 Pharmaceuticals
2nd Nov 20233:34 pmRNSEroxon Awarded “New Product of the Year” by Boots
31st Oct 20237:00 amRNSBlock Listing Application and Total Voting Rights
25th Oct 20237:00 amRNSEroxon® Granted Marketing Authorisation in Mexico
19th Oct 20237:00 amRNSEroxon Launches in the United Arab Emirates
10th Oct 20237:00 amRNSDirectors’/PDMR Dealing and Grant of Options
2nd Oct 20237:00 amRNSEuropean Patent Granted for MED3000 until 2040
18th Sep 20237:00 amRNSFutura Medical - Interim Results 2023
18th Aug 20237:00 amRNSFutura Medical - Notice of Interim Results
31st Jul 20237:00 amRNSFutura Medical - Total Voting Rights
18th Jul 202311:04 amRNSBoard Change
17th Jul 20237:00 amRNSFutura/Haleon Enter US Commercialisation Agreement
30th Jun 20237:00 amRNSFutura Medical - Total Voting Rights
23rd Jun 20234:30 pmRNSRecording of Investor Seminar
22nd Jun 20233:19 pmRNSFutura Medical Annual General Meeting Results
22nd Jun 20237:00 amRNSFutura Medical AGM Statement
19th Jun 202310:25 amRNSCorrection - TR-1: Notification of major holdings
16th Jun 20234:05 pmRNSTR-1: Notification of major holdings
12th Jun 20238:23 amRNSExercise of Warrants
12th Jun 20237:00 amRNSMED3000 Granted US FDA Approval for OTC Sale
8th Jun 20237:00 amRNSFutura Medical Announces Investor Seminar
31st May 20237:00 amRNSBlock Listing Six Monthly Return
26th May 20237:00 amRNSNotice of AGM and availability of Annual Report
24th Apr 20237:00 amRNSTR-1: Notification of major holdings
18th Apr 20237:00 amRNSMED3000, Eroxon® UK Launch
6th Apr 202311:03 amRNSDirectors' / PDMR Dealing and Grant of Options
5th Apr 20237:00 amRNSFull Year Results ended 31 December 2022
29th Mar 20237:00 amRNSUpdate on MED3000 regulatory approval in the US
27th Mar 20235:24 pmRNSNotice of Preliminary Results 2022
14th Mar 20238:33 amRNSMED3000 commercial and US regulatory update
15th Feb 20237:00 amRNSMED3000 FM71 Presentation at ESSM Congress 2023
1st Feb 20231:26 pmRNSBlock Listing Applications to AIM
26th Jan 20237:00 amRNSPre-launch of MED3000 ahead of H1 2023 launch
12th Jan 202311:09 amRNSFutura Remuneration, Options & Total Voting Rights
15th Dec 20223:01 pmRNSTR-1: Notification of major holdings
13th Dec 20221:10 pmEQSFutura Medical 'on track' for launch in H1 2023
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.